NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hengsai Biotechnology

Hengsai Biotechnology

Private
ShanghaiHealthcare & Life Scienceshttps://kousai.vip

Last Round

Strategic

Dec 30, 2025

Total Funding Raised

$22.87M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Hengsai Biotechnology is a biotechnology company that develops therapeutic dendritic cell (DC) vaccines for the treatment of tumors, chronic viral infections, and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

dendritic cell vaccinepersonalized immunotherapyautologous cell therapycancer immunotherapycell therapydendritic cell therapycancer vaccinetherapeutic vaccinepersonalized medicineDC vaccinerelapsed and refractory tumorsclinical-stage biotechEBV-positive tumors

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hengsai Biotechnology Comparables

Compare Hengsai Biotechnology with similar companies based on industry and business-model similarity.

Hengsai Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CoImmune, Inc.
82%
Elios Therapeutics
80%
Diakonos Oncology
78%

Hengsai Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicDec 30, 2025
Series A ExtensionJan 17, 2024
Series ANov 27, 2023
Pre SeedApr 20, 2022

Hengsai Biotechnology Investors

Notable investors and investment history

Hengsai Biotechnology investors
InvestorRounds
中山创业投资有限公司Series A Extension
Fuhui Venture CapitalSeries A, Pre Seed
Beijing Chengming Private Equity Fund Management Co., Ltd.Series A Extension
Zhongshan Cuiheng Group Co., Ltd.Series A Extension
Tasly CapitalStrategic
Zhongshan Venture Capital Co., Ltd.Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 30, 2025

    Led by Tasly Capital

  • Jan 17, 2024

    $4M raised from Beijing Chengming and Zhongshan Venture Capital.

Hengsai Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hengsai Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hengsai Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2018
Last FundingDec 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.